Dr Raza Bokhari, Executive Co-Chairman & Interim CEO CSE:HUGE, OTC:FSDDF, FRA:0K9
FSD has 25,000 square feet available for production at its Ontario facility with an additional 220,000 square feet currently in development.
FSD’s R&D platform is focused on cannabinoids and their potential for widespread clinical applications. FSD has a strong interest in acquiring an R&D platform with the capability of producing synthetic cannabinoids and intends to create FDA approved medications that will be commercialized internationally.
SOURCE: FSD Pharma